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Abstract. Melatonin is known to reduce the growth of 
endocrine-responsive breast cancers by interacting with 
estrogen signaling pathways. Estrogens play an important role 
in breast cancer, but also in various types of tissues, including 
vascular tissue. Estrogen sulfatase (STS) converts inactive 
estrogen sulfates into active estrogens, whereas estrogen sulfo-
transferase (EST) sulfonates estrogens to estrogen sulfates. 
Therefore, STS and EST are considered to be involved in 
the regulation of local estrogen levels in hormone-dependent 
tumors and in non-pathologic tissues, such as those of the 
vascular system. Estrogens have a major impact on the vascula-
ture, influencing vascular function, the expression of adhesion 
proteins, angiogenesis and the inflammatory state. In this study, 
we investigated the status of STS and EST in human umbilical 
vein endothelial cells (HUVECs) and the modulatory effects 
of melatonin. Both STS and EST were highly expressed in the 
HUVECs. The enzymatic activity correlated with the expres-
sion levels in these cells. Our findings also demonstrated that 
melatonin, at physiological concentrations, modulated the 
synthesis and transformation of biologically active estrogens 
in HUVECs through the inhibition of STS activity and expres-
sion, and the stimulation of EST activity and expression. Since 
melatonin decreased the STS levels and increased the EST 
levels, it modified the dynamic steady-state equilibrium of 
estrogen sulfates by increasing the inactive estrogen levels and 
decreasing the active estrogen levels. Therefore, melatonin may 
modulate the known different biological actions of estrogens in 
endothelial cells, as well as in estrogen-dependent tumors and 
non-pathologic tissues.
Introduction
The local metabolism and synthesis of estrogens, resulting 
from the interactions of various enzymes, is considered to 
play a crucial role in the pathogenesis and development of 
hormone-dependent carcinomas, but also in various organs 
and systems, including female reproductive organs, bone, 
liver, central nervous system and vascular system (1-3). The 
major circulating form of plasma estrogen is estrone sulfate, 
a biologically inactive form of estrogen, which acts as an 
estrogen reserve, which can be formed from sulfated estrogens 
by steroid sulfatase (STS), which is present in both normal and 
tumor tissues (Fig. 1). The plasma concentrations of estrogen 
sulfates are 50- to 15-fold higher than those of unconjugated 
estrogens, such as estrone, estradiol and estriol, and their 
half-life in plasma (10-12 h) is considerably longer than that 
of estrone and estradiol (20-30 min) (4,5). Estrogen sulfates 
are therefore thought to act as a reservoir for the formation of 
active estrogens via the action of STS (6), which converts inac-
tive estrogen sulfates to estrone and 17β-estradiol. Estrone is 
then reduced to the biologically active estrogen, 17β-estradiol, 
by 17β'-hydroxysteroid dehydrogenase type 1 (17β-HSD1) (7). 
STS is ubiquitously expressed in mammalian tissues and target 
organs, including the liver, endometrium, ovaries, bone, brain, 
prostate, white blood cells and adipocytes, but it is particularly 
prevalent in the placenta and in breast carcinomas (6,7). The 
potency of estrogenic hormones is generally reduced during 
the metabolic process to inactive products in target tissues, 
and this contributes to the modulation of the overall biological 
actions of estrogens. Estrogen sulfotransferase (EST) sulfonates 
estrogens to form biologically inactive estrogen sulfates (8) and 
it is distributed in a wide range of normal human tissues, such 
as the kidneys, liver, gastrointestinal tract, vascular tissue and 
breasts (Fig. 1). In breast carcinoma, EST activity and expression 
tend to be decreased (9). Therefore, STS and EST are consid-
ered to be involved in the regulation of in situ estrogen levels in 
various human tissues and hormone-dependent tumors (6,10).
Melatonin, the main secretory product of the pineal gland, is 
well known to reduce the growth and development of estrogen-
responsive breast cancers (11-14). Melatonin exerts its oncostatic 
effects in hormone-dependent breast cancer by interfering at 
Melatonin affects the dynamic steady-state equilibrium  
of estrogen sulfates in human umbilical vein endothelial  
cells by regulating the balance between estrogen  
sulfatase and sulfotransferase
ALICIA GONZÁLEZ,  CARLOS MARTÍNEZ-CAMPA,  CAROLINA ALONSO-GONZÁLEZ  and  SAMUEL COS
Department of Physiology and Pharmacology, School of Medicine, University of Cantabria 
and Valdecilla Biomedical Research Institute (IDIVAL), ES-39011 Santander, Spain
Received April 27, 2015;  Accepted September 25, 2015
DOI: 10.3892/ijmm.2015.2360
Correspondence to: Dr Samuel Cos, Department of Physiology and 
Pharmacology, School of Medicine, University of Cantabria, Avenida 
Cardenal Herrera Oria s/n, ES-39011 Santander, Spain
E-mail: coss@unican.es
Key words: melatonin, human umbilical vein endothelial cells, 
estrogens, sulfatase, estrogen sulfotransferase, estrogen sulfates
GONZÁLEZ et al:  MELATONIN AND ESTROGEN SULFATE LEVELS IN ENDOTHELIAL CELLS1672
different levels of the estrogen signaling pathways (15,16). One of 
the mechanisms through which this occurs involves the regulation 
by melatonin of the expression and activity of several enzymes 
(aromatase, STS, 17β-HSD1 and EST) that are responsible for 
the local synthesis of estrogens; thus, melatonin functions as a 
selective estrogen enzyme modulator (17,18). Melatonin exerts 
its regulatory actions on estrogen-producing enzymes in tumor 
cells, surrounding fibroblasts and endothelial cells. In endothe-
lial cells, melatonin regulates the aromatase pathway, which 
transforms androgens into estrogens (19-21). Melatonin reduces 
the activity and expression of aromatase mainly by inducing a 
significant downregulation in aromatase expression, specifically 
driven by promoter I.7, the major promoter directing aromatase 
expression in endothelial cells (19). In addition, melatonin has 
been shown to exert anti-angiogenic effects by reducing endo-
thelial cell proliferation, invasion, migration and tube formation, 
through a downregulatory effect on vascular endothelial growth 
factor (VEGF) in endothelial cells (22,23). These results piqued 
our interest into the possible effects of melatonin on other 
enzymes involved in the local biotransformation of steroids in 
endothelial cells. Thus, our objective in the present study, was to 
analyze the activity and expression of EST and STS in human 
umbilical vein endothelial cells (HUVECs) and to elucidate the 
possible modulatory effects and mechanisms of melatonin.
Materials and methods
Cells and culture conditions. The HUVECs were purchased 
from the American Tissue Culture Collection (ATCC; 
Rockville, MD, USA). They were maintained as monolayer 
cultures in 75 cm2 plastic culture flasks in Vascular Cell Basal 
Medium (VCBM) supplemented with Endothelial Cell Growth 
kit-BBE (both from ATCC) which consisted of 2% fetal bovine 
serum (FBS), 0.2% bovine brain extract, 5 ng/ml recombinant 
human epidermal growth factor (rhEGF), 10 mM L-glutamine, 
0.75 U/ml heparin sulfate, 1 µg/ml hydrocortisone hemisuc-
cinate, 50 µg/ml ascorbic acid, penicillin (20 U/ml) and 
streptomycin (20 µg/ml) (Sigma-Aldrich, Madrid, Spain) at 
37˚C in a humid atmosphere containing 5% CO2. To avoid 
genetic mutation and low viability, HUVECs at no more than 
6 passages were used in the following experiments.
Measurement of STS activity. STS activity in the HUVECs was 
assayed by the formation of estrone from a labeled substrate 
([6,7-3H(N)]-estrone sulfate ammonium salt) (24). The HUVECs 
were seeded onto 75 cm2 plastic culture flasks in VCBM 
supplemented with 2% FBS. When a homogenous monolayer 
of pre-confluent HUVECs was established, the medium was 
aspirated and the cultured cells were harvested and seeded onto 
6-well plates (3x105 cells/well) in VCBM supplemented with 
2% FBS. One day later, the medium was replaced with fresh 
medium (1 ml/plate) containing 20 nM [6,7-3H(N)]-estrone 
sulfate ammonium salt (NEN Life Science Products, Boston, 
MA, USA) (57.3 Ci/mM) in the presence of either 1 mM, 
1 µM or 1 nM melatonin, or its diluent (control; ethanol at a 
final concentration <0.001%). Following 20 h of incubation, 
the culture dishes were placed on ice for 15 min to condense 
any water vapour and 0.5 ml of the medium was transferred 
to tubes containing 2.5 ml of toluene, vortexed for 45 sec and 
centrifuged at 1,000 x g for 10 min at 4˚C. The resulting organic 
phase was added to vials with scintillation cocktail (National 
Diagnostics, Atlanta, GA, USA) and counted using a beta 
counting system (Beckman LS60001C Scintillation Counter; 
Beckman Instruments, Atlanta, GA, USA). The amount of 
radioactivity measured in the [3H]-toluene was corrected by 
subtracting the blank values from each sample, obtained by 
incubating dishes containing medium but no cells with the 
tritiated estrone. As previously described (18), the values were 
also corrected by taking into account the fractional retention of 
tritium in medium throughout the procedure of incubation and 
processing, utilizing parallel dishes containing medium plus 
known amounts of [3H] estrone (NEN Life Science Products). 
The fractional retention of tritium in medium throughout the 
incubation and processing of samples was always >92%.
Measurement of EST activity. EST activity in the HUVECs was 
evaluated by the formation of E1-S from [2,4,6,7-3H(N)]-estrone, 
as previously described (25). The HUVECs were seeded onto 
75 cm2 plastic culture flasks in VCBM supplemented with 2% FBS. 
When a homogenous monolayer of pre-confluent HUVECs was 
reached, the medium was aspirated and the cultured cells were 
harvested and seeded onto 6-well plates (3x105 cells/well) in 
VCBM supplemented with 2% FBS. One day later, the medium 
was replaced with fresh medium (1 ml/plate) supplemented with 
2% dicyclohexylcarbodiimide (DCC), containing 2 µM estrone 
including 10 nM [2,4,6,7-3H(N)]-estrone (NEN Life Science 
Products) (100 Ci/mM), 7 mM MgCl2, 50 mM Tris-HCl pH 7.4, 
phosphoadenosine phosphosulfate (PAPS) at a final concentra-
tion of 20 µM, in the presence of either melatonin (1 mM, 1 µM 
or 1 nM), or its diluent (control; ethanol at a final concentra-
tion <0.001%). Following 48 h of incubation, the medium was 
transferred to tubes containing a cold mix of 4 ml of chloroform 
plus 0.375 ml of 0.25 M Tris-HCl pH 8.7, vortexed for 45 sec and 
centrifuged at 600 x g for 5 min at 4˚C. The resulting aqueous 
phase was added to vials with scintillation cocktail and counted 
using a beta counting system. Values were corrected for blanks 
and tritium recovery (>87%) was as described above.
Measurement of mRNA expression of STS and EST. The mRNA 
expression of different enzymes was carried out by reverse tran-
scription-quantitative polymerase chain reaction (RT-qPCR) of 
the HUVECs, after incubation of cells with either melatonin or 
the vehicle for 4 h, as described in a previous study of ours (39). 
Total cellular RNA was purified using the NucleoSpin 
RNA II kit (Macherey-Nagel GmbH & Co., Düren, Germany) 
following the manufacturer's instructions. The integrity of the 
RNA was assessed by electrophoresis in ethidium bromide-
stained 1.2% agarose-Tris-borate EDTA gels. The absorbance 
ratio A260/A280 nm was >1.8. For cDNA synthesis, 1 µg of 
total RNA was denaturated at 65˚C for 10 min and reverse 
transcribed for 50 min at 45˚C using the cDNA synthesis kit 
(Bioline, London, UK) in a final volume of 20 µl in the pres-
ence of 500 ng of oligo(dT)12-18 primer. qPCR (MX3000; 
Stratagene, La Jolla, CA, USA) was performed using Brilliant 
SYBR-Green PCR Master Mix (Stratagene) following the 
manufacturer's instructions. The pairs of human oligonucle-
otides (Sigma Genosys Ltd., Cambridge, UK) used as primers 
are indicated in Table I. S14 mRNA expression was used as 
a control. PCRs were performed for 40 cycles for quantitative 
analysis using the annealing temperature indicated in Table I 
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for 60 sec, the extension being carried out at 72˚C for 45 sec and 
the denaturation at 95˚C for 50 sec. Each product was electro-
phoresed on ethidium bromide-stained 2% agarose-Tris-borate 
gels to corroborate that the product amplified corresponded 
to the adequate length. Finally, the mRNA expression levels 
of target genes were normalized to S14 mRNA expression. 
Each reaction was run in triplicate. Melting curve analysis was 
performed using dissociation curves to verify that only a single 
product with no primer-dimers was amplified.
Statistical analysis. The data are expressed as the means ± stan-
dard errors of the mean (SEM) of 6 independent experiments. 
Statistical differences between groups were analyzed by one 
way analysis of variance (ANOVA), followed by the Student-
Newman-Keuls test. Results were considered statistically 
significant difference at a value of p<0.05.
Results
Effects of melatonin on STS activity and expression. We first 
examined the effects of various concentrations of melatonin on 
the activity and mRNA expression of STS. Physiological concen-
trations of melatonin (1 nM) induced a significant (p<0.001) 
inhibition of STS activity in the HUVECs (Fig. 2A). The 
concentrations of melatonin in the micromolar range (1 µM) 
were also effective at reducing (p<0.001) the conversion of 
estrone sulphate to estrone.
With the aim of determining whether the inhibitory effects 
of melatonin on STS activity are due to the downregulation 
of STS expression, we incubated the HUVECs with either 
melatonin (1 mM, 1 µM or 1 nM) or the vehicle [the diluent 
(control), ethanol at a final concentration <0.001%] for 4 h, and 
total RNA was isolated to perform RT-qPCR with specific 
primers for human STS. As a control, the same samples were 
subjected to RT-qPCR with specific primers for the house-
keeping gene, S14, a ribosomal protein component of the 
40S subunit. Treatment of the HUVECs with physiological 
concentrations of melatonin (1 nM) led to a significant and 
potent inhibition (40%) of STS mRNA expression compared to 
the controls (Fig. 2B). The supraphysiological concentrations 
of melatonin (1 µM) were also effective at reducing (p<0.001) 
STS mRNA expression.
Figure 1. Schematic diagram representing the enzymatic mechanisms involved in the local formation and transformation of estrogens in endothelial cells. Estrogen 
sulfates act as a reservoir for the formation of active estrogens and their concentration depends on the action of sulfatase, which hydrolyzes biologically inactive 
estrogen sulfates to active estrogens (estrone and estradiol), and estrogen sulfotransferase which sulfonates estrogens to biologically inactive estrogen sulfates.
Table I. Primers used for the amplification of mRNA transcripts of STS, EST and S14 (control).
mRNA Sequence bp [ ] nM T
STS F: 5'-TCCGTTCCTGCTTGTCTTGTC-3' 197 200 57˚C
 R: 5'-CCTGGTCCGATGTGAAGTAGATG-3'  200 57˚C
EST F: 5'-AGACTCATTTGCCACCTGAACTTC-3 133 200 59˚C
 R: 5'-GGATGACCAGCCACCATTAGAAAG-3'  100 59˚C
S14 F: 5'-TCACCGCCCTACACATCAAAC-3' 159 100
 R: 5'-TCCTGCGAGTGCTGTCAGAG-3'  100
bp, product size (base-pairs); [ ] nM, primers concentration; T, annealing temperature; F, sense (forward) primer; R, antisense (reverse) primer; 
STS, steroid sulfatase; EST, estrogen sulfotransferase.
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Effects of melatonin on EST activity and expression. In a 
second set of experiments, the effects of melatonin on the 
activity and mRNA expression of EST were examined. The 
activity of EST was significantly stimulated by treatment of 
the HUVECs with physiological concentrations (1 nM) of 
melatonin (Fig. 3A). When the HUVECs were incubated for 
4 h with 1 nM melatonin, the mRNA expression of EST was 
significantly increased (p<0.001) (Fig. 3B). Higher concen-
trations of melatonin (1 µM) also induced an increase in the 
mRNA expression of EST, although to a lesser extent than that 
triggered by treatment with 1 nM melatonin (Fig. 3B).
Discussion
Estrogens are potent steroid hormones with pleiotropic effects 
potentially causing diverse modulatory effects on vascular 
functions and the endothelial dysfunction that is associated with 
an increased risk of cancer and cardiovascular disease (26-28). 
Estrogens synthesized in peritumoral endothelial cells also 
play a role in the growth and progression of estrogen-dependent 
tumors, such as breast tumors (4). Estrogens are secreted 
primarily by the ovaries, the placenta and the testes, and they 
are also produced by peripheral steroidogenic conversion. Two 
major pathways are implicated in providing peripheral sources 
of estrogen in human peripheral tissues. One is the aromatase 
pathway which transforms androgens into estrogens (29,30), 
and the other is the sulfatase pathway which converts estrogen 
sulfates into estrogens by the enzyme, STS (5). During the 
past decades, research has been directed mainly towards the 
development of aromatase inhibitors (31), and as a result, 
potent, well-tolerated and highly selective aromatase inhibitors 
are now available for use in clinical practice (32). However, 
there is a growing awareness of the role that STS may play 
in regulating the formation of estrogenic steroids since the 
estrone sulfatase pathway is the major route of estrogen forma-
tion in breast tumors (6,33). Estrone sulfate is quantitatively 
the most important precursor of estradiol and STS activity is 
40-500-fold greater than aromatase activity in breast cancer 
Figure 2. (A) Effects of melatonin (1 mM, 1 µM or 1 nM), or its diluent (control, 
ethanol at 0.001% final concentration) on basal estrogen sulfatase (STS) activity 
in human umbilical vein endothelial cells (HUVECs), determined after 20 h of 
incubation with the indoleamine. (B) Effects of melatonin (1 mM, 1 µM or 
1 nM), or its diluent on STS mRNA expression in HUVECs. Cells were incu-
bated with melatonin or ethanol (0.001%) (control) for 4 h. Data are expressed 
as the percentage of the control group (means ± SEM). ap<0.001 vs. control; 
bp<0.001 vs. melatonin 1 mM.
Figure 3. (A) Effects of 48 h of incubation with melatonin (1 mM, 1 µM or 
1 nM) or its diluent (control, ethanol at 0.001% final concentration) on estrogen 
sulfotransferase (EST) activity in human umbilical vein endothelial cells 
(HUVECs). (B) Effects of melatonin (1 mM, 1 µM and 1 nM), or its diluent on 
the mRNA expression of EST in HUVECs. Cells were incubated with mela-
tonin or ethanol (0.001%) (control) for 4 h. Data are expressed as the percentage 
of the control group (means ± SEM). ap<0.001 vs. control; bp<0.01 vs. control; 
cp<0.001 vs. melatonin 1 mM; dp<0.001 vs. melatonin 1 µM.
Figure 4. Melatonin tends to activate and overexpress estrogen sulfotrans-
ferase (EST) and to decrease sulfatase (STS) activity and expression, which 
alters the dynamic steady-state equilibrium of estrogen sulfates and may result 
in the accumulation of estrogen sulfates in human umbilical vein endothelial 
cells (HUVECs).
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tissues. Whereas STS decreases estrogen sulfate levels and 
increases active estrogen levels, EST sulfonates estrogens to 
biologically inactive estrogen sulfates and increases the level of 
estrogen sulfates (4,9,34).
Melatonin is well known for its oncostatic proper-
ties (11,12,14,16). This indoleamine exerts its oncostatic 
effects on estrogen-dependent breast tumors mainly through 
two mechanisms: interfering with the estrogen signaling path-
ways at the estrogen receptor level (16,35,36) and regulating 
the activity and expression of the enzymes involved in local 
estrogen biosynthesis in tumor cells and peritumoral fibro-
blasts (16,20,21,37,38).
To date, it has not been clearly determined whether STS 
and EST activity and expression are present in HUVECs. 
The present study firstly demonstrated that STS and EST are 
expressed in HUVECs, and are able to modulate the concen-
tration of estrogen sulfates, and therefore, estrogen synthesis in 
endothelial cells. Melatonin, at physiological (1 nM) concen-
trations, induced a significant inhibition of STS activity in the 
HUVECs and this inhibitory effect was due to the downregu-
lation of STS expression. To the best of our knowledge, this 
is the first time that the effects of melatonin on STS activity 
and expression in endothelial cells have been established. In 
relation to the modulatory effects of melatonin on STS, it is 
known that melatonin inhibits STS activity and expression 
in vitro in human breast cancer cells (18) and glioma cells (39). 
This modulatory effect of melatonin on STS has also been 
described in vivo, in rats bearing 7,12-dimethylbenz[a]anthra-
cene (DMBA)-induced mammary tumors (40). The inhibition 
of STS activity and expression in breast cancer with high doses 
of synthetic antiestrogens, such as tamoxifen, has been also 
described (41).
Estrogen sulfate concentrations are dependent on its 
inactivation by STS and its production by EST (balance of 
STS/EST). Recently, it has been described that EST is highly 
expressed in human vascular endothelial and smooth muscle 
cells and the modulation of its activity and expression regulates 
the levels of active estrogens in these cells, thereby affecting 
the physiology and pathophysiology of vascular walls (42,43). 
In this study, physiological concentrations of melatonin (1 nM) 
significantly increased EST activity and expression in 
HUVECs. This upregulation of EST induced by melatonin has 
also been described in human breast cancer cells (9,18,20). This 
indolamine, at physiological concentrations in human breast 
cancer cells, increased EST activity by almost 2-fold and EST 
expression up to 3-fold (9,18,20). These results concur with the 
findings of other previous on estrogen-responsive human breast 
cancer cells. Melatonin was shown to exert a direct concen-
tration-dependent anti-proliferative effect and only melatonin 
concentrations closer to 1 nM (concentrations similar to those 
found in the serum of most mammals during the nocturnal 
period) were effective at decreasing cell proliferation, whereas 
supra- or subphysiological concentrations lacked these antipro-
liferative effects (11,12,14).
STS and EST are involved in the regulation of in situ 
estrogen sulfate levels in HUVECs. The balance between 
these two enzymes determines the concentration of estrogen 
sulfates and consequently, the concentration of active estrogens 
in endothelial cells (4,6). In normal breast tissue, STS activity 
and expression are very weak whereas, the activity and expres-
sion of EST are very high. The equilibrium between the two 
enzymes is displaced towards the accumulation of estrogen 
sulfates, the major precursor of local estrogen production. 
However, in breast carcinoma tissue the formation of the active 
17β-estradiol predominates, as STS tends to be overexpressed, 
whereas the expression of EST is frequently decreased (4,9). In 
HUVECs, since melatonin decreases the activity and expression 
of STS, which transforms the estrone sulfates to estrogens, and 
increases the activity and expression of EST, which inactivates 
estrogens, it results in the modification of the dynamic steady-
state equilibrium of estrogen sulfates by increasing estrogen 
sulfate levels and decreasing active estrogen levels (Fig. 4). 
Melatonin regulates the activity and expression of the enzymes 
involved in the local synthesis of estrogens in endothelial cells 
in a similar manner to the activity and expression of enzymes 
in normal mammary normal tissue.
In conclusion, the findings presented herein point to a role 
for melatonin in mediating the synthesis and transformation 
of biologically active estrogens in HUVECs by inhibiting the 
mRNA expression and activity of the enzyme involved in estra-
diol formation (STS) and by stimulating the mRNA expression 
and activity of the enzyme responsible for the inactivation of 
estradiol and formation of the biologically inactive estrogen 
sulfates (EST). Melatonin decreased STS and increased EST 
levels, and as a result, modified the dynamic steady-state equi-
librium of estrogen sulfates through increased estrogen sulfate 
levels and decreased active estrogen levels. Thus, melatonin 
may modulate the physiology and pathophysiology of vascular 
tissue.
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